Amphastar Pharma

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Amphastar Pharma excels in Q1 2023, eyes growth opportunities

Amphastar Pharma's Q1 2023 showcased robust financial performance, driven by revenue growth and strategic product initiatives.
While facing challenges in market dynamics and margin management, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial strength, Amphastar Pharma demonstrates resilience and potential for sustained success.

Amphastar Pharma excels in Q2 with revenue growth and innovation

Amphastar Pharma's Q2 2023 performance reflects strong revenue growth, improved profitability, and operational efficiency, underpinned by robust sales across key products.
While facing challenges such as FDA approval delays and pipeline setbacks, the company's strategic focus on proprietary products and innovation presents opportunities for sustained growth.
By capitalizing on market demand, enhancing margins, and advancing its product pipeline, Amphastar is poised to navigate challenges and capitalize on opportunities for long-term success.

Amphastar Pharma excels in Q3 with robust revenue growth

Amphastar Pharma delivered impressive financial results in Q3 2023, marked by significant revenue growth and profitability improvements.
While facing challenges in sustaining rapid sales growth and managing debt obligations, the company's strategic focus on product expansion and market presence presents growth opportunities.
Overall, Amphastar Pharma's strong performance, diverse product portfolio, and financial stability position it well for future growth and value creation for stakeholders.

Amphastar Pharma excels in Q4 2023, eyes growth opportunities

Amphastar Pharma's Q4 2023 performance reflects robust growth in revenues, profit, and net income, driven by strategic focus and product demand.
While facing challenges like lower gross margins and capacity expansions, the company is poised for growth through innovation and market opportunities.
Opportunities lie in R&D advancements, product launches, and financial strength, positioning Amphastar Pharma for continued success and expansion.

Amphastar Pharma excels in Q1 2024, eyes growth through innovation

Amphastar Pharma's Q1 2024 showcases strong financial performance and strategic focus on product innovation and market expansion. While facing challenges in pricing and regulatory landscape, the company is poised for growth through new product launches and market penetration strategies.

Amphastar Pharma reports revenue growth amidst margin challenges and regulatory hurdles

Amphastar Pharma's Q3 performance showed revenue growth driven by key products.
While facing challenges in net income and margins, the company aims for sustainable growth.
Opportunities lie in product launches, market expansion, and regulatory progress.
Overall, Amphastar Pharma navigates financial challenges with strategic initiatives.

Amphastar Pharma reports solid Q4 results, eyes growth opportunities ahead

Amphastar Pharma's Q4 2024 performance reflects revenue growth, strong net income, and strategic partnerships driving future sales acceleration. While facing challenges like declining Glucagon sales and competitive pressures, the company's strengths in R&D and capital investments position it for long-term success. Opportunities in new product approvals, partnership expansions, and market growth present avenues for revenue diversification and sustained profitability. Overall, Amphastar's financial outlook, though cautious for 2025, hints at a resilient business strategy geared towards future growth and market resilience.

Amphastar Pharma reports stable Q1 performance amidst strategic shifts

Amphastar Pharma's Q1 performance reflects stability in key product sales despite a slight revenue decline, with a focus on strategic partnerships and product expansion. The company's strengths lie in its recognition by the FDA, stable sales of BAQSIMI and Primatene MIST, and progress on regulatory filings for new products. Challenges include monitoring tariff impacts, addressing revenue decline, and navigating the transition to a diversified product portfolio, while opportunities exist in partnerships, product expansion, and future growth prospects.

Amphastar Pharma posts strong Q2 earnings amidst strategic expansion

Amphastar Pharma's Q2 performance reflects solid financial results, driven by key product growth and operational expansion. While facing regulatory challenges and increased expenses, the company's strategic focus on innovation and manufacturing efficiency positions it well for future growth. Clear communication with investors and a proactive financial strategy are key strengths that can help navigate challenges and capitalize on growth opportunities.

Amphastar Pharma excels in Q3 2025, eyes growth in 2026

Amphastar Pharma's Q3 2025 showcased strong financial performance and strategic advancements. While facing challenges in margins and expenses, the company's growth outlook for 2026 remains positive. Opportunities in product expansion, manufacturing, and regulatory progress position the company for future success. Balancing strengths, addressing challenges, and seizing opportunities will be key for sustained growth and profitability.

Amphastar Pharma reports resilient Q4 performance and eyes growth

Amphastar Pharma navigated challenges in sales decline with strong financial performance. Strategic FDA approvals and product growth position the company for future success. Anticipated revenue growth and pipeline advancements offer promising opportunities for expansion.